Security Snapshot

Arcus Biosciences, Inc. - Common Stock, par value $0.0001 (RCUS) Institutional Ownership

CUSIP: 03969F109

13F Institutional Holders and Ownership History from Q1 2018 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

176

Shares (Excl. Options)

91.55MFull value: 91,552,089 · shares · 30 Sep 2026

Price

$25.83

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-72,311
Value change
-$34,908,033
Number of holders
176
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
127,225,749
SEC-reported price per share
$18.14
Insider filing price
$18.14
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • RCUS - Arcus Biosciences, Inc. - Common Stock, par value $0.0001 is tracked under CUSIP 03969F109.
  • 176 institutions reported positions in Q3 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 229 to 176 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $3.78BFull value: $3,781,046,896 · USD · 30 Jun 2026
    to
    $2.36BFull value: $2,363,790,904 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 176 institutions filings for Q3 2026.

Open SEC evidence

Security key

03969F109

13F reference period

Q3 2026

13F holders

176

13D/G owners

3

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
3
Security
RCUS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 25% -3.5% $882,093,013 31,424,760 0% Gilead Sciences, Inc. 05 Aug 2026
BlackRock, Inc. 10% +11% $303,514,602 +$65,766,227 12,736,927 +28% BlackRock, Inc. 31 Dec 2025
Point72 Asset Management, L.P. 4.1% -28% $58,921,714 -$20,381,232 4,332,479 -26% Point72 Asset Management, L.P. 30 Sep 2025
As of 30 Sep 2026, 176 institutional investors reported holding
91.55MFull value: 91,552,089 · shares · 30 Sep 2026
shares of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 (RCUS). This represents 72% of the company’s total
127.23MFull value: 127,225,749 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
62%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
GILEAD SCIENCES, INC. 25% 31,424,760 55% $811,701,551
WELLINGTON MANAGEMENT GROUP LLP 4.8% 6,169,222 0.03% $159,351,005
STATE STREET CORP 4.4% 5,570,292 0% $143,880,642
VANGUARD PORTFOLIO MANAGEMENT LLC 3.5% 4,440,422 0.01% $114,696,100
VANGUARD CAPITAL MANAGEMENT LLC 3.1% 3,931,334 0% $101,546,357
Woodline Partners LP 2.2% 2,854,798 0.22% $73,739,432
Janus Henderson Group Ltd. 2% 2,538,648 0.03% $65,636,744
GEODE CAPITAL MANAGEMENT, LLC 1.9% 2,480,755 0% $64,088,874
Siren, L.L.C. 1.9% 2,420,430 1.5% $62,519,707
Fisher Asset Management, LLC 1.5% 1,918,497 0.01% $49,554,776
GOLDMAN SACHS GROUP INC 1.3% 1,637,095 0% $42,286,164
SAMLYN CAPITAL, LLC 1.1% 1,394,945 0.61% $36,031,429
DIMENSIONAL FUND ADVISORS LP 1.1% 1,390,719 0.01% $35,921,229
TWO SIGMA INVESTMENTS, LP 1% 1,328,002 0.02% $34,302,292
Vestal Point Capital, LP 1% 1,300,000 0.87% $33,579,000
Invesco Ltd. 0.93% 1,184,953 0% $30,607,337
Aberdeen Group plc 0.83% 1,056,679 0.04% $27,294,019
BANK OF AMERICA CORP /DE/ 0.72% 915,248 0% $23,640,864
Soleus Capital Management, L.P. 0.68% 862,000 0.79% $22,265,460
BAKER BROS. ADVISORS LP 0.66% 844,816 0.1% $21,821,597
Ikarian Capital, LLC 0.58% 734,559 3.8% $18,973,659
Parkman Healthcare Partners LLC 0.53% 675,516 1.6% $17,448,578
VANGUARD FIDUCIARY TRUST CO 0.5% 633,133 0% $16,353,825
Sofinnova Investments, Inc. 0.49% 626,178 0.8% $16,174,178
First Turn Management, LLC 0.45% 577,693 2% $14,921,810

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
35
Headline period
Q3 2026
Rows shown
1-25 of 35
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 91,552,089 $2,363,790,904 -$34,908,033 $25.83 176
2026 Q2 122,674,585 $3,781,046,896 +$137,672,077 $30.83 229
2026 Q1 119,104,471 $2,572,923,108 -$79,675,032 $21.60 209
2025 Q4 121,424,353 $2,893,305,835 +$498,497,157 $23.83 208
2025 Q3 100,610,243 $1,368,169,306 +$17,470,409 $13.60 186
2025 Q2 99,735,332 $811,386,525 +$23,005,595 $8.14 181
2025 Q1 97,195,653 $762,981,433 +$76,941,552 $7.85 183
2024 Q4 83,908,968 $1,249,338,646 -$21,214,675 $14.89 185
2024 Q3 53,324,923 $815,463,718 +$21,618,657 $15.29 184
2024 Q2 51,955,193 $791,285,512 -$15,709,425 $15.23 191
2024 Q1 52,828,671 $997,275,069 +$741,376 $18.88 169
2023 Q4 52,818,611 $1,008,878,346 -$1,266,933 $19.10 181
2023 Q3 52,811,112 $947,947,087 -$30,726,648 $17.95 184
2023 Q2 54,702,646 $1,110,123,478 -$11,409,103 $20.31 177
2023 Q1 55,490,875 $1,012,137,432 +$17,396,401 $18.24 177
2022 Q4 53,808,832 $1,112,728,096 +$17,661,819 $20.68 199
2022 Q3 52,505,739 $1,373,608,654 -$54,087 $26.16 171
2022 Q2 52,444,913 $1,329,092,467 -$15,970,235 $25.34 162
2022 Q1 50,609,470 $1,598,261,880 -$43,817,366 $31.56 146
2021 Q4 50,826,972 $2,056,609,533 +$107,109,155 $40.47 136
2021 Q3 48,251,727 $1,682,950,642 +$59,932,851 $34.87 127
2021 Q2 45,147,112 $1,239,729,813 +$11,589,356 $27.46 125
2021 Q1 44,736,322 $1,254,917,338 +$7,899,154 $28.08 143
2020 Q4 44,575,673 $1,157,187,273 +$10,417,742 $25.96 143
2020 Q3 44,391,126 $760,991,949 +$17,571,170 $17.14 127
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .